原发免疫性血小板减少症(immune thrombocytopenia,ITP),既往被称为特发性血小板减少性紫癜,是一种以血小板破坏增加、骨髓巨核细胞成熟障碍、血小板生成减少为特点的血小板减少综合征,约占出血性疾病的30%,是临床上最常见的自身免疫性出血性疾病。该病在任何年龄均可发病,年发病率5~10/10万人,30~60岁患者以女性为主,60岁以上无性别差异〔1〕。本文对近年来ITP的发病机制及治疗进展做一综述。 Immune thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenic purpura, is a thrombocytopenic syndrome characterized by increased platelet destruction, impaired bone marrow megakaryocyte maturation, and reduced platelet production , Accounting for about 30% of hemorrhagic diseases, is the most common clinical autoimmune bleeding disease. The disease can occur at any age, the annual incidence of 5 to 10/10 million, 30 to 60-year-old patients with predominantly women, 60 years of age without sex differences [1]. This article reviews the pathogenesis and treatment progress of ITP in recent years.